Sarath Ramachandran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarath Ramachandran has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alessio Ciulli
University of Dundee
5 shared publications - Jayaraman Sivaraman
Department of Biological Sciences National University of Singapore Singapore Singapore
4 shared publications - Kevin Haubrich
European Molecular Biology Laboratory, 69117 Heidelberg, Germany
3 shared publications - Alena Kroupova
Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, DD1 5JJ, Dundee, UK
2 shared publications - David Zollman
Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK
2 shared publications Denzel Gonzales
Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, Dundee, UK
2 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular glues) in clinical development. Biophysical and structural investigation of CRBN has been limited by current constructs that either require co-expression with the adaptor DDB1 or inadequately represent full-length protein, with high-resolution structures of degrader ternary complexes remaining rare. We present the design of CRBNmidi, a construct that readily expresses from E. coli with high yields as soluble, stable protein without DDB1. We benchmark CRBNmidi for wild-type functionality through a suite of biophysical techniques and solve high-resolution co-crystal structures of its binary and ternary complexes with degraders. We qualify CRBNmidi as an enabling tool to accelerate structure-based discovery of the next generation of CRBN based therapeutics.
- 15 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessDesign of a Cereblon construct for crystallographic and biophysical studies of protein degraders
The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular glues) in clinical development. Biophysical and structural investigation of CRBN has been limited by current constructs that either require co-expression with the adaptor DDB1 or inadequately represent full-length protein, with high-resolution structures of degrader ternary complexes remaining rare. We present the design of CRBNmidi, a construct that readily expresses from E. coli with high yields as soluble, stable protein without DDB1. We benchmark CRBNmidi for wild-type functionality through a suite of biophysical techniques and solve high-resolution co-crystal structures of its binary and ternary complexes with degraders. We qualify CRBNmidi as an enabling tool to accelerate structure-based discovery of the next generation of CRBN based therapeutics.
- Open Access
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular glues) in clinical development. Biophysical and structural investigation of CRBN has been limited by current constructs that either require co-expression with the adaptor DDB1 or inadequately represent full-length protein, with high-resolution structures of degraders ternary complexes remaining rare. We present the design of CRBN midi , a construct that readily expresses from E. coli with high yields as soluble, stable protein without DDB1. We benchmark CRBN midi for wild-type functionality through a suite of biophysical techniques and solve high-resolution co-crystal structures of its binary and ternary complexes with degraders. We qualify CRBN midi as an enabling tool to accelerate structure-based discovery of the next generation of CRBN based therapeutics. One sentence summary: A novel Cereblon construct (CRBN midi ) allows structural and biophysical enablement of ligand and degrader design
Open AccessDesign of a Cereblon construct for crystallographic and biophysical studies of protein degraders
The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular glues) in clinical development. Biophysical and structural investigation of CRBN has been limited by current constructs that either require co-expression with the adaptor DDB1 or inadequately represent full-length protein, with high-resolution structures of degraders ternary complexes remaining rare. We present the design of CRBN midi , a construct that readily expresses from E. coli with high yields as soluble, stable protein without DDB1. We benchmark CRBN midi for wild-type functionality through a suite of biophysical techniques and solve high-resolution co-crystal structures of its binary and ternary complexes with degraders. We qualify CRBN midi as an enabling tool to accelerate structure-based discovery of the next generation of CRBN based therapeutics. One sentence summary: A novel Cereblon construct (CRBN midi ) allows structural and biophysical enablement of ligand and degrader design
- Open Access
- 10 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2
The Src homology 2 (SH2) domain recognizes phosphotyrosine (pY) post translational modifications in partner proteins to trigger downstream signaling. Drug discovery efforts targeting the SH2 domains have long been stymied by the poor drug-like properties of phosphate and its mimetics. Here, we use structure-based design to target the SH2 domain of the E3 ligase suppressor of cytokine signaling 2 (SOCS2). Starting from the highly ligand-efficient pY amino acid, a fragment growing approach reveals covalent modification of Cys111 in a co-crystal structure, which we leverage to rationally design a cysteine-directed electrophilic covalent inhibitor MN551. We report the prodrug MN714 containing a pivaloyloxymethyl (POM) protecting group and evidence its cell permeability and capping group unmasking using cellular target engagement and in-cell 19F NMR spectroscopy. Covalent engagement at Cys111 competitively blocks recruitment of cellular SOCS2 protein to its native substrate. The qualified inhibitors of SOCS2 could find attractive applications as chemical probes to understand the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation.
- 10 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessStructure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2
The Src homology 2 (SH2) domain recognizes phosphotyrosine (pY) post translational modifications in partner proteins to trigger downstream signaling. Drug discovery efforts targeting the SH2 domains have long been stymied by the poor drug-like properties of phosphate and its mimetics. Here, we use structure-based design to target the SH2 domain of the E3 ligase suppressor of cytokine signaling 2 (SOCS2). Starting from the highly ligand-efficient pY amino acid, a fragment growing approach reveals covalent modification of Cys111 in a co-crystal structure, which we leverage to rationally design a cysteine-directed electrophilic covalent inhibitor MN551. We report the prodrug MN714 containing a pivaloyloxymethyl (POM) protecting group and evidence its cell permeability and capping group unmasking using cellular target engagement and in-cell 19F NMR spectroscopy. Covalent engagement at Cys111 competitively blocks recruitment of cellular SOCS2 protein to its native substrate. The qualified inhibitors of SOCS2 could find attractive applications as chemical probes to understand the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation.
- 1 April 2021
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 67, 110-119
Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues
- 1 April 2021
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 67, 110-119
Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues
- Open Access
- 10 June 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase
The suppressor of cytokine signaling 2 (SOCS2) acts as substrate recognition subunit of a Cullin5 E3 ubiquitin ligase complex. SOCS2 binds to phosphotyrosine-modified epitopes as degrons for ubiquitination and proteasomal degradation, yet the molecular basis of substrate recognition has remained elusive. Here, we report co-crystal structures of SOCS2-ElonginB-ElonginC in complex with phosphorylated peptides from substrates growth hormone receptor (GHR-pY595) and erythropoietin receptor (EpoR-pY426) at 1.98 Å and 2.69 Å, respectively. Both peptides bind in an extended conformation recapitulating the canonical SH2 domain-pY pose, but capture different conformations of the EF loop via specific hydrophobic interactions. The flexible BG loop is fully defined in the electron density, and does not contact the substrate degron directly. Cancer-associated SNPs located around the pY pocket weaken substrate-binding affinity in biophysical assays. Our findings reveal insights into substrate recognition and specificity by SOCS2, and provide a blueprint for small molecule ligand design.
- 10 June 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Open AccessStructural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase
The suppressor of cytokine signaling 2 (SOCS2) acts as substrate recognition subunit of a Cullin5 E3 ubiquitin ligase complex. SOCS2 binds to phosphotyrosine-modified epitopes as degrons for ubiquitination and proteasomal degradation, yet the molecular basis of substrate recognition has remained elusive. Here, we report co-crystal structures of SOCS2-ElonginB-ElonginC in complex with phosphorylated peptides from substrates growth hormone receptor (GHR-pY595) and erythropoietin receptor (EpoR-pY426) at 1.98 Å and 2.69 Å, respectively. Both peptides bind in an extended conformation recapitulating the canonical SH2 domain-pY pose, but capture different conformations of the EF loop via specific hydrophobic interactions. The flexible BG loop is fully defined in the electron density, and does not contact the substrate degron directly. Cancer-associated SNPs located around the pY pocket weaken substrate-binding affinity in biophysical assays. Our findings reveal insights into substrate recognition and specificity by SOCS2, and provide a blueprint for small molecule ligand design.
- Open Access
- 22 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (36) , 57943-57954
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
- 22 July 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (36) , 57943-57954
Open AccessStructural basis for exploring the allosteric inhibition of human kidney type glutaminase
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
- 1 March 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 471 (4) , 409-415
Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis
- 1 March 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 471 (4) , 409-415
Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis
- 1 November 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 467 (3) , 577-582
Structural basis of mapping the spontaneous mutations with 5-flurouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis
- 1 November 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 467 (3) , 577-582
Structural basis of mapping the spontaneous mutations with 5-flurouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis
- Open Access
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (37) , 25611-25623
Dimeric Switch of Hakai-truncated Monomers during Substrate Recognition
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (37) , 25611-25623
Open AccessDimeric Switch of Hakai-truncated Monomers during Substrate Recognition